drugset
Drugs / Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
last change Feb 2022 re-read 3 minutes ago

Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine

Vaccine

Developed for
Japanese encephalitis
Investigated by
International Centre for Diarrhoeal Disease Research, Bangladesh · PATH

Trials 1

today NCT02514746 · Ph 4
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02514746 Jul 2015 → Dec 2016 Japanese encephalitis PATH Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02514746 ↗
Modality Vaccine “The live attenuated SA 14-14-2 JE vaccine (CD-JEV) is one of three vaccines prequalified by the World Health Organization (WHO) to prevent JE.” PMID 35243320 ↗ Feb 2022
Route Subcutaneous “0.5 mL subcutaneous injection” NCT02514746 ↗